tscan.com - TCRX Operating profit EBITDA
EBITDA demonstrates high volatility, where the 0.00 indicator expresses the state of the metric. The financial stability of TScan Therapeutics (TCRX) remains uncertain due to its development stage and reliance on external capital. The brand's high authority in immuno-oncology is based on the creation of precise T-cell therapies. Meanwhile, the market value has already priced in early tests, with new drivers expected from phase II trials.
Summary analytical data breakdowns for TScan Therapeutics, Inc. (TCRX)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Capital TScan Therapeutics|TCRX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient TScan Therapeutics Inc|TCRX - Company Aggregate Debts|Debt to Book Value TScan Therapeutics|TCRX - Company Long-Term Debts|Company Short-Term Debts TScan Therapeutics|Immediate Liquidity Ratio tscan.com
- earnings and market ratios statistics:
TCRX - Net Income|Expected Net Income TScan Therapeutics|TCRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio TScan Therapeutics Inc|TCRX - PEG Multiple|Business Value to Operating Income Before Depreciation TScan Therapeutics|TCRX - Operating profit EBITDA|Net earnings per one share for the last twelve months TScan Therapeutics|TCRX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months tscan.com|TCRX - Earnings growth in current year|Earnings growth forecast for next year TScan Therapeutics
Summary company analytics:TCRX - TScan Therapeutics
This metric measures the net financial result from core operations, allowing the investor to assess the actual efficiency of cash generation before interest and taxes. By monitoring operating profit in cash terms, the impact of vendor costs on TScan Therapeutics (TCRX) contract research for T-cell therapy is captured, where any deviations in the curve signal rising outsourcing costs or a loss of control over production processes.
Who TScan Therapeutics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit before deduction of amortization PSNL (Personalis, Inc.)|Company profit before taxes, interest and amortization ERAS|Profit before payment of interest, taxes and amortization Delcath Systems DCTH|Operating income before deduction of amortization Y-mAbs Therapeutics Inc (YMAB)|Aura Bio - Operating profit EBITDA|Candel Therapeutics (CADL) - Operating profit before deduction of amortization|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group (SLS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Operating profit before amortization CTOR (Citius Oncology Inc.)|Operating profit before deduction of amortization HURA (TuHURA Biosciences, Inc.)|TARA (Protara Tx) - Income before deduction of interest, taxes and amortization|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization WHWK (Aadi Bioscience, Inc.)|Champions Oncology Corp - Operating profit EBITDA|Income before deduction of interest, taxes and amortization XBIT (XBiotech Inc.)|CVM: Operating profit EBITDA|Profit before interest, taxes and amortization OS Therapies, Inc. (OSTX)|Profit before payment of interest, taxes and amortization Radiopharm Theranostics|ARTV: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ANL|Operating profit EBITDA Veru Inc (VERU)|Profit before payment of interest, taxes and amortization Tempest Tx TPST|XLO (Xilio Therapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Enochian BioSciences - Operating profit EBITDA|Profit before interest, taxes and amortization Mural Oncology plc|KAPA (kairospharma.com) - Operating profit before deduction of amortization|OnKure Therapeutics (OKUR) - Operating profit EBITDA|Operating profit before deduction of amortization GDTC|CRIS (Curis Corp) - Company profit before taxes, interest and amortization|Operating profit EBITDA APLM|Operating income before deduction of amortization tharimmune.com|Operating profit EBITDA ADVB (Advanced Biomed)|GNPX - Operating profit before deduction of amortization|CLDI - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization sunshinebiopharma.com SBFM|XBIO (xeneticbio.com) - Operating profit before deduction of amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization AON (AONC)|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Elevation Oncology - Operating profit before deduction of amortization|ICAD: Operating profit before amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
